Patents Assigned to Dermavant Sciences GmbH
-
Patent number: 11938099Abstract: Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis or plaque psoriasis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3. Also described are clinical endpoints for treatment of subjects diagnosed with chronic mild to moderate plaque psoriasis for greater than or equal to 6 months, wherein about 3% to about 20% of body surface area was affected, and Physician Global Assessment (PGA) score was greater than or equal to 2.Type: GrantFiled: September 1, 2023Date of Patent: March 26, 2024Assignee: DERMAVANT SCIENCES GMBHInventors: John E. Kraus, James Lee
-
Publication number: 20230414534Abstract: Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis or plaque psoriasis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3. Also described are clinical endpoints for treatment of subjects diagnosed with chronic mild to moderate plaque psoriasis for greater than or equal to 6 months, wherein about 3% to about 20% of body surface area was affected, and Physician Global Assessment (PGA) score was greater than or equal to 2.Type: ApplicationFiled: September 1, 2023Publication date: December 28, 2023Applicant: Dermavant Sciences GmbHInventors: John E. KRAUS, James LEE
-
Patent number: 11827605Abstract: The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.Type: GrantFiled: October 28, 2022Date of Patent: November 28, 2023Assignee: DERMAVANT SCIENCES GMBHInventors: Channa K. Jayawickreme, Susan H. Smith, Cunyu Zhang, William Zuercher
-
Publication number: 20230225987Abstract: The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.Type: ApplicationFiled: June 24, 2021Publication date: July 20, 2023Applicant: Dermavant Sciences GmbHInventors: Piyush JAIN, Robert Michael LEMING, Glenn TABOLT, Alan Scott COLBORN
-
Publication number: 20230190673Abstract: Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis or plaque psoriasis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3. Also described are clinical endpoints for treatment of subjects diagnosed with chronic mild to moderate plaque psoriasis for greater than or equal to 6 months, wherein about 3% to about 20% of body surface area was affected, and Physician Global Assessment (PGA) score was greater than or equal to 2.Type: ApplicationFiled: February 2, 2023Publication date: June 22, 2023Applicant: Dermavant Sciences GmbHInventors: John E. KRAUS, James LEE
-
Publication number: 20230174445Abstract: The present invention provides processes for the preparation of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and novel intermediates used therein. In some embodiments the 3, 5-Dihydroxy-4-isopropyl-trans-stilbene is prepared from (E)-2-chloro-2-isopropyl-5-styrylcyclohexane-1,3-dione. Also disclosed are crystal forms of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and pharmaceutical compositions comprising same.Type: ApplicationFiled: February 3, 2023Publication date: June 8, 2023Applicant: Dermavant Sciences GmbHInventors: Ian Paul ANDREWS, Nicholas CALANDRA, Tyler Andrew DAVIS, Ravinder Reddy SUDINI
-
Publication number: 20230126208Abstract: The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.Type: ApplicationFiled: December 15, 2022Publication date: April 27, 2023Applicant: Dermavant Sciences GmbHInventors: Sujatha D. SONTI, Joey Roger THOMAS, Jon LENN, Leandro SANTOS, Justin WHITEMAN, Michael Quinn DOHERTY, Mary BEDARD, Piyush JAIN
-
Publication number: 20230124135Abstract: The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.Type: ApplicationFiled: October 28, 2022Publication date: April 20, 2023Applicant: Dermavant Sciences GmbHInventors: Channa K. JAYAWICKREME, Susan H. SMITH, Cunyu ZHANG, William ZUERCHER
-
Patent number: 11622945Abstract: The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.Type: GrantFiled: December 21, 2018Date of Patent: April 11, 2023Assignee: DERMAVANT SCIENCES GMBHInventors: Sujatha D. Sonti, Joey Roger Thomas, Jon Lenn, Leandro Santos, Justin Whiteman, Michael Quinn Doherty, Mary Bedard, Piyush Jain
-
Publication number: 20230106782Abstract: Topical compositions and methods for using topical compositions comprising tapinarof to treat chronic mild to moderate plaque psoriasis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with chronic mild to moderate plaque psoriasis for greater than or equal to 6 months, wherein about 3% to about 20% of body surface area was affected, and Physician Global Assessment (PGA) score was greater than or equal to 2.Type: ApplicationFiled: May 2, 2022Publication date: April 6, 2023Applicant: Dermavant Sciences GmbHInventors: John E. KRAUS, James LEE
-
Patent number: 11617724Abstract: The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.Type: GrantFiled: November 9, 2017Date of Patent: April 4, 2023Assignee: DERMAVANT SCIENCES GMBHInventors: Sujatha D. Sonti, Joey Roger Thomas, Jon Lenn, Leandro Santos, Justin Whiteman, Michael Quinn Doherty, Mary Bedard, Piyush Jain
-
Patent number: 11612573Abstract: The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.Type: GrantFiled: September 30, 2019Date of Patent: March 28, 2023Assignee: DERMAVANT SCIENCES GMBHInventors: Sujatha D. Sonti, Joey Roger Thomas, Jon Lenn, Leandro Santos, Justin Whiteman, Michael Doherty, Mary Bedard, Piyush Jain
-
Patent number: 11597692Abstract: The present invention provides processes for the preparation of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and novel intermediates used therein. In some embodiments the 3, 5-Dihydroxy-4-isopropyl-trans-stilbene is prepared from (E)-2-chloro-2-isopropyl-5-styrylcyclohexane-1,3-dione. Also disclosed are crystal forms of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and pharmaceutical compositions comprising same.Type: GrantFiled: February 12, 2021Date of Patent: March 7, 2023Assignee: DERMAVANT SCIENCES GMBHInventors: Ian Paul Andrews, Nicholas Calandra, Tyler Andrew Davis, Ravinder Reddy Sudini
-
Patent number: 11590088Abstract: Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis or plaque psoriasis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3. Also described are clinical endpoints for treatment of subjects diagnosed with chronic mild to moderate plaque psoriasis for greater than or equal to 6 months, wherein about 3% to about 20% of body surface area was affected, and Physician Global Assessment (PGA) score was greater than or equal to 2.Type: GrantFiled: July 22, 2022Date of Patent: February 28, 2023Assignee: DERMAVANT SCIENCES GMBHInventors: John E. Kraus, James Lee
-
Patent number: 11548853Abstract: The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.Type: GrantFiled: January 28, 2022Date of Patent: January 10, 2023Assignee: DERMAVANT SCIENCES GMBHInventors: Channa K. Jayawickreme, Susan H. Smith, Cunyu Zhang, William Zuercher
-
Publication number: 20220362171Abstract: Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis or plaque psoriasis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3. Also described are clinical endpoints for treatment of subjects diagnosed with chronic mild to moderate plaque psoriasis for greater than or equal to 6 months, wherein about 3% to about 20% of body surface area was affected, and Physician Global Assessment (PGA) score was greater than or equal to 2.Type: ApplicationFiled: July 22, 2022Publication date: November 17, 2022Applicant: Dermavant Sciences GmbHInventors: John E. KRAUS, James Lee
-
Patent number: 11497718Abstract: Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3.Type: GrantFiled: November 13, 2019Date of Patent: November 15, 2022Assignee: DERMAVANT SCIENCES GMBHInventors: John E. Kraus, James Lee
-
Patent number: 11458108Abstract: The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.Type: GrantFiled: December 21, 2018Date of Patent: October 4, 2022Assignee: DERMAVANT SCIENCES GMBHInventors: Sujatha D. Sonti, Joey Roger Thomas, Jon Lenn, Leandro Santos, Justin Whiteman, Michael Quinn Doherty, Mary Bedard, Piyush Jain
-
Patent number: 11267788Abstract: The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.Type: GrantFiled: May 27, 2021Date of Patent: March 8, 2022Assignee: DERMAVANT SCIENCES GMBHInventors: Channa K. Jayawickreme, Susan H. Smith, Cunyu Zhang, William Zuercher
-
Patent number: 10961175Abstract: The present invention provides processes for the preparation of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and novel intermediates used therein. In some embodiments the 3, 5-Dihydroxy-4-isopropyl-trans-stilbene is prepared from (E)-2-chloro-2-isopropyl-5-styrylcyclohexane-1,3-dione. Also disclosed are crystal forms of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and pharmaceutical compositions comprising same.Type: GrantFiled: April 15, 2020Date of Patent: March 30, 2021Assignee: DERMAVANT SCIENCES GMBHInventors: Ian Paul Andrews, Nicholas Calandra, Tyler Andrew Davis, Ravinder Reddy Sudini